Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE

被引:63
作者
Bian, HJ [1 ]
Hammer, J [1 ]
机构
[1] Hoffmann La Roche Inc, Sect Bioinformat Genet & Genom, Nutley, NJ 07110 USA
关键词
TEPITOPE; HLA-DR; epitope prediction; vaccine; bioinformatics;
D O I
10.1016/j.ymeth.2004.06.002
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
TEPITOPE is a prediction model that has been successfully applied to the in silico identification of T cell epitopes in the context of oncology, allergy, infectious diseases, and autoimmune diseases. Like most epitope prediction models, TEPITOPE's underlying algorithm is based on the prediction of HLA-II peptide binding, which constitutes a major bottleneck in the natural selection of epitopes. An important step in the design of subunit vaccines is the identification of promiscuous HLA-II ligands in sets of disease-specific gene products. TEPITOPE's user interface enables the systematic prediction of promiscuous peptide ligands for a broad range of HLA-binding specificity. We show how to apply the TEPITOPE prediction model to identify T cell epitopes, and provide both a road map and examples of its successful application. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:468 / 475
页数:8
相关论文
共 10 条
[1]   In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program [J].
Cochlovius, B ;
Stassar, M ;
Christ, O ;
Raddrizzani, L ;
Hammer, J ;
Mytilineos, I ;
Zöller, M .
JOURNAL OF IMMUNOLOGY, 2000, 165 (08) :4731-4741
[2]   Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 [J].
Consogno, G ;
Manici, S ;
Facchinetti, V ;
Bachi, A ;
Hammer, J ;
Conti-Fine, BM ;
Rugarli, C ;
Traversari, C ;
Protti, MP .
BLOOD, 2003, 101 (03) :1038-1044
[3]  
de Lalla C, 1999, J IMMUNOL, V163, P1725
[4]   PEPTIDE BINDING-SPECIFICITY OF HLA-DR4 MOLECULES - CORRELATION WITH RHEUMATOID-ARTHRITIS ASSOCIATION [J].
HAMMER, J ;
GALLAZZI, F ;
BONO, E ;
KARR, RW ;
GUENOT, J ;
VALSASNINI, P ;
NAGY, ZA ;
SINIGAGLIA, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (05) :1847-1855
[5]   PRECISE PREDICTION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II PEPTIDE INTERACTION BASED ON PEPTIDE SIDE-CHAIN SCANNING [J].
HAMMER, J ;
BONO, E ;
GALLAZZI, F ;
BELUNIS, C ;
NAGY, Z ;
SINIGAGLIA, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (06) :2353-2358
[6]   Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11 [J].
Manici, S ;
Sturniolo, T ;
Imro, MA ;
Hammer, J ;
Sinigaglia, F ;
Noppen, C ;
Spagnoli, G ;
Mazzi, B ;
Bellone, M ;
Dellabona, P ;
Protti, MP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05) :871-876
[7]   Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins [J].
Panigada, M ;
Sturniolo, T ;
Besozzi, G ;
Boccieri, MG ;
Sinigaglia, F ;
Grassi, GG ;
Grassi, F .
INFECTION AND IMMUNITY, 2002, 70 (01) :79-85
[8]  
Schroers R, 2002, CANCER RES, V62, P2600
[9]   T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1 [J].
Stassar, MJJG ;
Raddrizzani, L ;
Hammer, J ;
Zöller, M .
IMMUNOBIOLOGY, 2001, 203 (05) :743-755
[10]   Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices [J].
Sturniolo, T ;
Bono, E ;
Ding, JY ;
Raddrizzani, L ;
Tuereci, O ;
Sahin, U ;
Braxenthaler, M ;
Gallazzi, F ;
Protti, MP ;
Sinigaglia, F ;
Hammer, J .
NATURE BIOTECHNOLOGY, 1999, 17 (06) :555-561